

Zika Virus Infections - Pipeline Review, H1 2020

https://marketpublishers.com/r/Z36B576AADBEN.html

Date: June 2020

Pages: 274

Price: US\$ 2,000.00 (Single User License)

ID: Z36B576AADBEN

Abstracts

Zika Virus Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H1 2020, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 15, 42, 22 and 4



respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 13 and 12 molecules, respectively. Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline



projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Zika Virus Infections - Overview

Zika Virus Infections - Therapeutics Development

Zika Virus Infections - Therapeutics Assessment

Zika Virus Infections - Companies Involved in Therapeutics Development

Zika Virus Infections - Drug Profiles

Zika Virus Infections - Dormant Projects

Zika Virus Infections - Discontinued Products

Zika Virus Infections - Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Zika Virus Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Zika Virus Infections - Pipeline by Activirosomes Ltd, H1 2020

Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, H1 2020

Zika Virus Infections - Pipeline by AIM ImmunoTech Inc, H1 2020

Zika Virus Infections - Pipeline by Akshaya Bio Inc, H1 2020

Zika Virus Infections - Pipeline by Aravive Inc, H1 2020

Zika Virus Infections - Pipeline by Bharat Biotech Ltd, H1 2020

Zika Virus Infections - Pipeline by Biken Co Ltd, H1 2020

Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2020

Zika Virus Infections - Pipeline by BioNet- Asia Co Ltd, H1 2020

Zika Virus Infections - Pipeline by Biotron Ltd, H1 2020

Zika Virus Infections - Pipeline by BravoVax Co Ltd, H1 2020

Zika Virus Infections - Pipeline by CanSino Biologics Inc, H1 2020

Zika Virus Infections - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020

Zika Virus Infections - Pipeline by Cidara Therapeutics Inc, H1 2020

Zika Virus Infections - Pipeline by Ciloa, H1 2020

Zika Virus Infections - Pipeline by Clayton Biotechnologies Inc, H1 2020



Zika Virus Infections - Pipeline by Cocrystal Pharma Inc, H1 2020

Zika Virus Infections - Pipeline by Codagenix Inc, H1 2020

Zika Virus Infections - Pipeline by Emergent BioSolutions Inc, H1 2020

Zika Virus Infections - Pipeline by Emergex Vaccines Ltd, H1 2020

Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, H1 2020

Zika Virus Infections - Pipeline by Enyo Pharma SA, H1 2020

Zika Virus Infections - Pipeline by Etubics Corp, H1 2020

Zika Virus Infections - Pipeline by Excivion Ltd, H1 2020

Zika Virus Infections - Pipeline by Expres2ion Biotechnologies ApS, H1 2020

Zika Virus Infections - Pipeline by Future Medicine Co Ltd, H1 2020

Zika Virus Infections - Pipeline by GeneOne Life Science Inc, H1 2020

Zika Virus Infections - Pipeline by GeoVax Labs Inc, H1 2020

Zika Virus Infections - Pipeline by Greffex Inc, H1 2020

Zika Virus Infections - Pipeline by GT Biopharma Inc, H1 2020

Zika Virus Infections - Pipeline by Hawaii Biotech Inc, H1 2020

Zika Virus Infections - Pipeline by Heat Biologics Inc, H1 2020

Zika Virus Infections - Pipeline by HSRx Group, H1 2020

Zika Virus Infections - Pipeline by Humabs BioMed SA, H1 2020

Zika Virus Infections - Pipeline by IDBiologics Inc, H1 2020

Zika Virus Infections - Pipeline by Immunomodulation Inc, H1 2020

Zika Virus Infections - Pipeline by Imutex Ltd, H1 2020

Zika Virus Infections - Pipeline by IMV Inc, H1 2020

Zika Virus Infections - Pipeline by Indian Immunologicals Ltd, H1 2020

Zika Virus Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2020

Zika Virus Infections - Pipeline by Johnson & Johnson, H1 2020

Zika Virus Infections - Pipeline by Kamada Ltd, H1 2020

Zika Virus Infections - Pipeline by KM Biologics Co Ltd, H1 2020

Zika Virus Infections - Pipeline by Macrophage Therapeutics Inc, H1 2020

Zika Virus Infections - Pipeline by Medigen Inc, H1 2020

Zika Virus Infections - Pipeline by Microbiotix Inc, H1 2020

Zika Virus Infections - Pipeline by Moderna Inc, H1 2020

Zika Virus Infections - Pipeline by NanoViricides Inc, H1 2020

Zika Virus Infections - Pipeline by Novalex Therapeutics Inc, H1 2020

Zika Virus Infections - Pipeline by Orgenesis Inc, H1 2020

Zika Virus Infections - Pipeline by Ostrich Pharma USA Inc, H1 2020

Zika Virus Infections - Pipeline by Palisades Therapeutics, H1 2020

Zika Virus Infections - Pipeline by Pharos Biologicals LLC, H1 2020

Zika Virus Infections - Pipeline by Phoenix Biotechnology Inc, H1 2020

Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H1 2020



Zika Virus Infections - Pipeline by Precision Virologics Inc, H1 2020

Zika Virus Infections - Pipeline by ProtInhi BV, H1 2020

Zika Virus Infections - Pipeline by Replikins Ltd, H1 2020

Zika Virus Infections - Pipeline by Riboscience LLC, H1 2020

Zika Virus Infections - Pipeline by Sanofi, H1 2020

Zika Virus Infections - Pipeline by Sementis Ltd, H1 2020

Zika Virus Infections - Pipeline by Spotlight Innovation Inc, H1 2020

Zika Virus Infections - Pipeline by Stabilitech Biopharma Ltd, H1 2020

Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, H1 2020

Zika Virus Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Zika Virus Infections - Pipeline by TechnoVax Inc, H1 2020

Zika Virus Infections - Pipeline by Themis Bioscience GmbH, H1 2020

Zika Virus Infections - Pipeline by Theravectys SA, H1 2020

Zika Virus Infections - Pipeline by Tiba Biotech LLC, H1 2020

Zika Virus Infections - Pipeline by Tychan Pte Ltd, H1 2020

Zika Virus Infections - Pipeline by Valneva SE, H1 2020

Zika Virus Infections - Pipeline by VBI Vaccines Inc, H1 2020

Zika Virus Infections - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020

Zika Virus Infections - Pipeline by Virocovax, H1 2020

Zika Virus Infections - Pipeline by Xenothera SAS, H1 2020

Zika Virus Infections - Dormant Projects, H1 2020

Zika Virus Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020

Zika Virus Infections - Discontinued Products, H1 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development for Zika Virus Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Activirosomes Ltd

Acuitas Therapeutics Inc

AIM ImmunoTech Inc

Akshaya Bio Inc

Aravive Inc

Bharat Biotech Ltd

Biken Co Ltd

BioCryst Pharmaceuticals Inc

BioNet- Asia Co Ltd

Biotron Ltd

BravoVax Co Ltd

CanSino Biologics Inc

Chugai Pharmaceutical Co Ltd

Cidara Therapeutics Inc

Ciloa

Clayton Biotechnologies Inc

Cocrystal Pharma Inc

Codagenix Inc

Emergent BioSolutions Inc

Emergex Vaccines Ltd

Ennaid Therapeutics LLC



Enyo Pharma SA

Etubics Corp

Excivion Ltd

Expres2ion Biotechnologies ApS

Future Medicine Co Ltd

GeneOne Life Science Inc

GeoVax Labs Inc

Greffex Inc

GT Biopharma Inc

Hawaii Biotech Inc

Heat Biologics Inc

HSRx Group

Humabs BioMed SA

IDBiologics Inc

Immunomodulation Inc

Imutex Ltd

IMV Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kamada Ltd

KM Biologics Co Ltd

Macrophage Therapeutics Inc

Medigen Inc

Microbiotix Inc

Moderna Inc

NanoViricides Inc

Novalex Therapeutics Inc

Orgenesis Inc

Ostrich Pharma USA Inc

Palisades Therapeutics

Pharos Biologicals LLC

Phoenix Biotechnology Inc

Plex Pharmaceuticals Inc

Precision Virologics Inc

ProtInhi BV

Replikins Ltd

Riboscience LLC

Sanofi



Sementis Ltd

Spotlight Innovation Inc

Stabilitech Biopharma Ltd

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

Themis Bioscience GmbH

Theravectys SA

Tiba Biotech LLC

Tychan Pte Ltd

Valneva SE

VBI Vaccines Inc

VenatoRx Pharmaceuticals Inc

Virocovax

Xenothera SAS



I would like to order

Product name: Zika Virus Infections - Pipeline Review, H1 2020

Product link: https://marketpublishers.com/r/Z36B576AADBEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/Z36B576AADBEN.html